Do glucagon-like peptide-1 based therapies alter the risk of late-onset inflammatory bowel disease?

The use of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) widely used to treat type 2 diabetes, has accelerated worldwide after it was approved for treating obesity by the U.S. Food and Drug Administration in 2021 and the European Medicines Agency in 2022. The use of semaglutide is likely to accelerate further in the future after a recent trial reported that semaglutide lowers the risk of adverse cardiovascular events by 20% in patients with overweight or obesity and previous cardiovascular disease but without diabetes [1].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research